Table 1.

Early-phase clinical trials using FAK inhibitor as combination therapy

Clinical trial IDFAK inhibitorMalignancyPhaseOther agent(s)Results (if any)
Completed trials NCT01938443GSK2256098Advanced solid tumorsIbTrametinib (MEK inhibitor)Stable disease >6 weeks = 67%a
NCT01778803VS-6063OvarianI/IbPaclitaxelDisease control rate = 64%b
Objective response rate = 18%c
Ongoing trials NCT02523014GSK2256098MeningiomaIIVismodegib (hedgehog pathway inhibitor)
NCT02546531VS-6063Advanced solid tumorsIPembrolizumab (PD-1 inhibitor), gemcitabine
NCT02758587VS-6063Pancreatic, mesothelioma, non-small cell lung cancer (NSCLC)I/IIAPembrolizumab (PD-1 inhibitor)
NCT02943317VS-6063OvarianI/IIAvelumab (PD-L1 inhibitor)
NCT03287271VS-6063OvarianI/IICarboplatin, paclitaxel
  • aStable disease includes those who do not meet criteria for progression (at least 20% increase of target lesions), partial response (at least 30% shrinkage of target lesions), or complete response (disappearance of all target lesions).

  • bDisease control rate includes stable disease, partial responses, and complete responses.

  • cObjective response rate includes partial responses and complete responses.